Scilex Holding SCLX 深 沪
等待开盘 08-15 09:30:00 美东时间
17.41
-3.590
-17.10%
华盛通- 最 高22.01
- 今 开21.90
- 成交量 48.56万股
- 最 低 16.60
- 昨 收 21.00
- 总市值 1.21亿
- 52周最高 43.05
- 市盈率 静 --
- 换手率 6.99%
- 52周最低 3.60
- 委 比 -38.27%
- 总股本 695.16万
- 历史最高 591.50
- 量 比 2.37
- 振 幅 25.76%
- 历史最低 0.00
- 每 手 1
- 风险率 11.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Scilex Holding Q2 EPS $(7.42) Misses $(0.91) Estimate, Sales $9.896M Miss $26.250M Estimate
Scilex Holding (NASDAQ:SCLX) reported quarterly losses of $(7.42) per share which missed the analyst consensus estimate of $(0.91) by 715.38 percent. This is a 31.61 percent increase over losses of $(10.85) per share
08-14 15:42
Scilex Moves Closer to Semnur Merger as SEC Clears Registration for Denali Acquisition Vote in September
Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of
08-13 18:05
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
Denali's Form S-4 registration statement has been approved by the SEC, enabling the proposed business combination with Semnur. The extraordinary general meeting of Denali shareholders to vote on this transaction is scheduled for September 3, 2025. Upon completion, the combined entity will operate as Semnur Pharmaceuticals, Inc. Scilex Holding Company, the parent of Semnur, specializes in non-opioid pain management solutions and has a diverse port...
08-13 10:00
美股牛股 | 公司获高额股权融资，VWAV飙涨近370%；CELC大涨超167%
公司获高额股权融资，VWAV飙涨近370%；乳腺癌药物实验效果积极，CELC大涨超167%；正式进军稳定币领域，MPU大涨超40%>>
07-29 19:19
Oramed Grants Scilex $27M Option To Repurchase Warrants, With Potential Note Extension To 2026
As previously disclosed, on September 21, 2023, Oramed Pharmaceuticals Inc. (the "Company") entered into and consummated the transactions contemplated by a Securities Purchase Agreement (as amended by that certain
07-23 21:47
Scilex Holding Company Concludes 2025 Annual Stockholders Meeting
An announcement from Scilex Holding Company ( ($SCLX) ) is now available. On Ju...
06-24 04:37
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
Scilex Holding Company, headquartered in Palo Alto, California, announced that its Board of Directors has deferred the previously announced record date of May 2, 2025, for its preferred stock dividend to stockholders. The new record date will be determined at the Board's discretion, with the right to change or revoke the dividend. Scilex focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chroni...
06-23 20:50
Scilex Holding Announces Publication On GLOPERBA Dosing Adjustments In Peer-Review Journal
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
06-06 00:10
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
Scilex Holding Company announced a peer-reviewed publication on GLOPERBA® dosing adjustments, particularly for patients with renal impairment. GLOPERBA®, the only liquid oral colchicine for gout flare prophylaxis, allows precise dosing to minimize toxicity risks. The study highlights optimal dosing levels for moderate (0.48 mg) and severe (0.3 mg) renal impairment, improving safety. The company focuses on non-opioid pain management products, incl...
06-05 16:05
Scilex Holding Presents Post-Hoc Analysis of C.L.E.A.R. Trial On Clinical Meaningfulness Of Safety And Efficacy Of SP-102 For Treatment of Lumbosacral Radicular Pain at ASIPP 2025
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
05-16 21:21
